AIP
CODX

Ameritas Investment Partners’s Co-Diagnostics CODX Stock Holding History

Ameritas Investment Partners’s Portfolio CODX Stock Details CODX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-76
Closed -$22K – 3090
2021
Q1 		$22K Hold
76
– – ﹤0.01% 2521
2020
Q4 		$21K Hold
76
– – ﹤0.01% 2440
2020
Q3 		$31K Hold
76
– – ﹤0.01% 2137
2020
Q2 		$44K Buy
+76
New +$34.7K ﹤0.01% 1907

Other funds holding CODX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PPA
Parametric Portfolio Associates Seattle, Washington $190B AUM 18.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
ARC
Advisor Resource Council Dallas, Texas $355M AUM 30.05% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Ameritas Investment Partners's CODX Position: Q2 2021 in Review

Ameritas Investment Partners sold out of Co-Diagnostics (CODX) in Q2 2021, closing a stake of 76 shares — an estimated $22K sold.

Ameritas Investment Partners first reported a position in CODX in Q2 2020 and held it in 4 quarters. The position peaked at $44K in Q2 2020. 88 funds tracked by Wall St. Rank hold CODX as of Q2 2021.

  • Ameritas Investment Partners reported no remaining Co-Diagnostics position as of Q2 2021 after selling out during the quarter.
  • Ameritas Investment Partners sold 76 Co-Diagnostics shares in Q2 2021, an estimated $22K.
  • Ameritas Investment Partners first reported a position in Co-Diagnostics in Q2 2020 and held it in 4 quarters.
  • Ameritas Investment Partners's Co-Diagnostics position peaked at $44K in Q2 2020.
  • 88 funds tracked by Wall St. Rank held Co-Diagnostics as of Q2 2021.

Based on Ameritas Investment Partners's 13F filing for Q2 2021, filed 6 Aug 2021.